How CVS built a healthcare empire it now plans to split

CVS Health plans to separate its retail pharmacies from Caremark and Aetna, splitting its $117 billion business into two publicly traded companies by early 2028; current shareholders are expected to own shares in both. The move reverses years of acquisitions and expansion into insurance and healthcare services. CVS has been cutting costs and closing stores as it grapples with rising medical costs in its insurance business.

Analysis

The key question is whether separation unlocks a valuation discount or merely makes two difficult businesses easier to price. A standalone retail pharmacy may lose negotiating leverage and shared infrastructure; the benefits of sharper management focus must exceed stranded corporate costs, duplicated systems and transition expense. On the other side, separating the insurer/PBM may reduce perceived conflicts for clients and regulators, but could also weaken the operational case for integrating drug benefits with care delivery. Neither outcome is established by the announcement.

Near term, expect the market to focus less on the headline and more on missing mechanics: debt allocation, retained contracts, shared-service agreements, separation costs, tax treatment and management incentives. Over 1–3 months, credible financial disclosures could narrow a conglomerate discount; vague terms or deterioration in either unit’s outlook could widen it. The planned 2028 timing leaves substantial execution and policy risk, including possible changes to PBM economics and continued pressure on retail pharmacy economics. Walgreens, Amazon Pharmacy and PBM competitors such as Express Scripts could benefit if customers use the transition to reconsider relationships, though any share gains are conditional, not automatic.

Contrarian view: a breakup is not inherently value-creating. Investors may be pricing strategic clarity before seeing the standalone cost base, while retaining both shares does not prevent index, mandate or income-oriented holders from selling one resulting company. No valuation or separation terms are supplied, so a directional trade is premature.

Key Decisions for Investors

• Treat CVS as an event-driven watch, not an automatic buy: await standalone segment financials and a quantified bridge from current corporate costs to post-separation costs before underwriting sum-of-parts upside.
• If disclosures show credible cost allocation, manageable transition expense and no material loss of customer contracts, consider a staged long CVS into the separation milestones; define the thesis as valuation re-rating, not assumed operating improvement. Reassess if guidance weakens or separation costs rise.
• Monitor the next 1–3 months for debt assignment, tax treatment, shared-service terms, contract-retention data and any separation timetable change. These are the key missing inputs; absent them, avoid a leveraged event position.
• Falsification: reduce or exit a breakup-re-rating thesis if management cannot provide auditable standalone economics, major clients signal they are reconsidering contracts, or either business’s operating outlook deteriorates enough to overwhelm any multiple uplift.